<DOC>
	<DOCNO>NCT02201004</DOCNO>
	<brief_summary>Primary Objectives : To assess effect tofogliflozin glycemic control comparison placebo add-on treatment insulin treatment term glycated hemoglobin ( HbA1c ) reduction period 16 week patient type 2 diabetes mellitus . To assess safety tofogliflozin combination insulin treatment throughout 52 week . Secondary Objectives : To assess effect tofogliflozin comparison placebo : - Body weight - Fasting plasma glucose ( FPG ) - Postprandial plasma glucose ( PPG ) To assess long term safety tolerability tofogliflozin .</brief_summary>
	<brief_title>TOFO Insulin Combination Trial</brief_title>
	<detailed_description>The total study duration screen patient approximately 1 year , include screen period 2 week , double-blinded placebo control treatment period 16 week , open-labeled extension period 36 week , follow-up period 3 day .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Inclusion criterion : Patients aged 2075 year old type 2 diabetes mellitus ( T2DM ) . Hemoglobin A1c ≥7.5 % ≤10.5 % FPG ≤220 mg/dL . Basal bolus ( BB ) , Bolus , Premix , Basal support oral therapy ( BOT ) regimens used 12 week screen . Stable dose ( /+20 % ) insulin change dose oral hypoglycemic agent 12 week screen . Only Dipeptidyl peptidase4 inhibitor allow basal support oral therapy ( BOT ) regimen . Body mass index ( BMI ) ≥18.5 kg/m^2 &lt; 35.0 kg/m^2 . No change antihypertensive , antihypercholesterolemia uric acid lower drug 4 week screen . Exclusion criterion : Type 1 diabetes mellitus . Pregnancy lactation . Severely uncontrolled glycemic situation . History metabolic acidosis , include diabetic ketoacidosis , within 1 year prior screen . History myocardial infarction , stroke , heart failure require hospitalization drug alcohol abuse within previous 6 month . A measured serum creatinine level great 2.0 mg/dL men 1.5 mg/dL woman . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≥2.5 time upper limit reference range central laboratory test facility . Has previously receive treatment investigational product . Has receive treatment another investigational product nonapproved drug within 3 month test provisional enrolment . Corticosteroid therapy 14 day total within 8 week test provisional enrolment ( exclude use localized effect , drug topical [ skin ] application , eye drop spray ) . Patients frequently experience orthostatic hypotension . Required change dose regimen follow drug within 4 week test provisional enrolment : Lipidlowering drug Antihypertensive drug Thyroid hormone preparation Uric acid lower drug The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>